Nom du produit:3-Hydrazino-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazine

IUPAC Name:5-hydrazinyl-3,4-diazatricyclo[9.4.0.0²,⁷]pentadeca-1(15),2,4,6,11,13-hexaene

CAS:802598-74-9
Formule moléculaire:C13H14N4
Pureté:95%+
Numéro de catalogue:CM337866
Poids moléculaire:226.28

Unité d'emballage Stock disponible Prix($) Quantité
CM337866-100mg in stock ȤƐœ
CM337866-250mg in stock džŪƚ
CM337866-1g 1-2 Weeks ȤȤdžœ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:802598-74-9
Formule moléculaire:C13H14N4
Point de fusion:-
Code SMILES:NNC1=NN=C2C(CCCC3=CC=CC=C32)=C1
Densité:
Numéro de catalogue:CM337866
Poids moléculaire:226.28
Point d'ébullition:
N° Mdl:
Stockage:2-8ºC

Column Infos

Bemcentinib
Bemcentinib is a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections. Extensive studies confirm the ability to combine bemcentinib with immune checkpoint inhibitors, chemotherapies and targeted therapies with the goal of improving a patient’s immune response and delaying the development of chemoresistance. Bemcentinib is currently being investigated in combination with immune checkpoint inhibition and chemotherapy in first line NSCLC patients harboring mutations in the STK11 gene, a known prognostic factor of poor response to existing therapies.

Related Products